Pharma Exec Blog
The Business of Pharmaceuticals
Skip to content
Archives
Now in Video, the Prix Galien Winners
“Salami-slicing” orphan drugs
European pharma: go easy on your lobbyists!
Europe: Go easy on your lobbyists
Contact
Home
/
PharmExec Blog
/
Follow Us
/
Podcasts
/
RSS
/
Bookstore
Magazine
Pharmaceutical Executive Magazine
Pharm Exec Europe Digest
Columnists
Product Managers Handbook
Consultants Confidential
Pharma Meetings
Agency Confidential
Special Reports
Hot Topics
Marketing
Sales
Deals
Regulatory
Strategy
Technology
Meetings
R & D
Profiles
Multimedia
Webcasts
Podcasts
Blog
Sponsored Content
Country Reports
White Papers
Pharm Exec 50
Industry Audit
Woman of the Year
Subscribe
Pharmaceutical Executive Magazine
Pharm Exec Europe Digest
Pharm Exec Direct Newsletter
Advertise
Magazine
Media Kit & BPA
E-Media Advertising
Careers
Directories
Supplier eDirectory
Products & Services
Contact Us
Editorial
Author Guidelines
Sales
Advertising
Lists
Reprints
Tag Archives:
new molecular entities
Combating Opioid Abuse With Science
By
Ben Comer
|
Published:
February 23, 2012
So far, the creative approaches industry has taken to develop tamper-resistant and abuse-deterrent opioid drugs have been largely matched by the ingenuity of those users who manage to tamper with and abuse those same formulations.
Posted in
FDA
,
R&D
,
Regulatory
,
Safety
,
Strategy
,
Technology
|
Also tagged
drug safety
,
FDA
,
opioids
|
3 Comments
Not Just Numbers: R&D Decline Measured in More Than NMEs
By
Jennifer Ringler
|
Published:
December 5, 2011
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
Posted in
R&D
|
Also tagged
Oliver Wyman
,
R&D
|
1 Comment
Combating Opioid Abuse With Science